Guardant Health Raises FY2026 Revenue Guidance Following Strong Q3 Growth
Guardant Health (GH) reported a strong third quarter with revenue increasing 36% year-over-year to $361 million, up from $265 million in the prior year. The company's oncology segment contributed significantly to this growth, posting a 25% increase compared to the same period last year. Driven by this momentum, management has raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion. Additionally, the company outlined long-term efficiency goals for its Shield product, targeting a cost per test of $200 by the end of 2028.
Tickers: $GH